Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
***Speaker Highlights***
for full faculty bio's, please visit our FACULTY page
Learn about Sara Whitlock, RET + Patient
Sara was diagnosed with stage IV RET+ lung cancer in 2010. Traditional chemo and radiation followed with great success. In the years since Sara has been on and off treatment several times. She is currently taking nivolumab and doing very well. Sara lives in Dayton, OH with her husband, JD, and two daughters Katie and Elena. Katie just headed off to college at Washington University in St. Louis while Elena is in the 10th grade. Sara has been an active advocate for the lung cancer community doing both fundraising, grant review, and she is a patient advocate for the Alliance for Clinical Trials in Oncology. She is living proof that life doesn't stop with a stage IV diagnosis!
Targeted Therapies in Lung Cancer Patient Forum
September 16, 2017
Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center
See below for our growing list of topics and presenters!
Register at cancerGRACE.org | Agenda is subject to change
| 8:30 – 10:00 am | The Many Faces of Progression Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies Dr. Karen Reckamp, City of Hope |
|
| 10:30 – noon |
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy?
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West
|
|
|
BREAKOUT SESSIONS |
||
|
1:00 – 2:30 pm
|
Presentations by Lung Cancer Sub-type *Available treatment options *Acquired resistance: How do you pick your next treatment? ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient
|
|
|
BREAKOUT SESSIONS |
||
|
2:50 – 4:00 pm
|
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger
|
|
GRACE would like to thank the following companies for their support of this forum:
 |
 |
 |
 |
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…